Binimetinib, also known as MEK162 (ARRY-162), is an oral, highly selective MEK inhibitor. In preclinical studies, MEK162 showed significant antitumor activities in cell lines and animal models. MEK162 is the first targeted therapy to show activity in patients with NRAS -mutated melanoma and might offer a new option for a cancer with few effective treatments.
Anon. Process for the preparation of 5-((4-bromo-2-fluorophenyl)amino)-4-fluoro-1-methyl-1H-benz[d]imidazole-6-carboxylic acid. IP.com Journal. Volume 15. Issue 12B. Pages 1pp.Journal; Patent. (2015).
Chen, Jian. Synthetic method of Binimetinib. Assignee Hunan Ouya Biological Co., Ltd., Peop. Rep. China. CN 105820124. (2016).
Huang, Xizhong; Peters, Malte; Schumacher, Karl Maria; Cao, Zhu Alexander; Gansert, Jennifer Lorraine; Chang, David Dong Eun; Beltran, Pedro. Combination therapy. Assignee Novartis Pharma AG, Switz.; Amgen Inc. WO 2013142182. (2013).
Wallace, Eli M.; Lyssikatos, Joseph P.; Marlow, Allison L.; Hurley, T. Brian; Koch, Kevin. Preparation of phenylaminobenzimidazolecarboxylates as mitogen activated protein kinase kinase (MEK) inhibitors. Assignee Array BioPharma, Inc., USA. US 20040116710. (2004).
